What initiates the formation of senile plaques? The origin of Alzheimer-like dementias in capillary haemorrhages

Medical Hypotheses

Volumn 71, Issue 3, 2008, Pages 347-359

  Stone, Jonathan ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; ARTICLE; BLEEDING; BRAIN CAPILLARY; BRAIN CORTEX; DEMENTIA; DOWN SYNDROME; FAMILIAL DISEASE; GENETIC REGULATION; HYPOTHESIS; ISCHEMIA; NERVE CELL; NERVOUS TISSUE; NEUROPIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SENILE PLAQUE; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CAPILLARIES; CEREBRAL CORTEX; HUMANS; MODELS, BIOLOGICAL; SENILE PLAQUES; UP-REGULATION;

EID: 47549115789     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.04.007     Document Type: Article

References (123)

1. Mandelkow E.M., and Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol 8 (1998) 425-427
2. Yanker B. New clues to Alzheimer's disease: unraveling the roles of amyloid and tau. Nature Med 2 (1996) 850-851
3. Hardy J., and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12 (1991) 383-388
4. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 924 (2000) 17-25
5. Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters, Zbl. ges. Neurol Psychiat 4 (1911) 356-385
6. Kraepelin E. Senile and pre-senile dementias. Psychiatrie: ein Lehrbuch für Studierende und Ärzte (1910), Johann Ambrosius Barth, Leipzig 553-632
7. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift Psychiatrie Psychisch-Gerichtliche Medizin (1907) 146-148
8. In: Boland B. (Ed). Cerbrovascular pathology in Alzheimer's disease (1997), The New York Academy of Sciences, New York
9. In: Goldman B. (Ed). Alzheimer's disease: vascular etiology and pathology (2002), The New York Academy of Sciences, New York
10. In: Goldman B. (Ed). Vascular factors in Alzheimer's disease (2000), The New York Academy of Sciences, New York
11. Hardy J.A., Mann D.M., Wester P., and Winblad B. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging 7 (1986) 489-502
12. Bell M.A., and Ball M.J. Neuritic plaques and vessels of visual cortex in aging and Alzheimer's dementia. Neurobiol Aging 11 (1990) 359-370
13. Kawai M., Cras P., and Perry G. Serial reconstruction of beta-protein amyloid plaques: relationship to microvessels and size distribution. Brain Res 592 (1992) 278-282
14. Miyakawa T. Vascular pathology in Alzheimer's disease. Ann N Y Acad Sci 977 (2002) 303-305
15. Miyakawa T., Kimura T., Hirata S., Fujise N., Ono T., Ishizuka K., et al. Role of blood vessels in producing pathological changes in the brain with Alzheimer's disease. Ann N Y Acad Sci 903 (2000) 46-54
16. Miyakawa T., Katsuragi S., Higuchi Y., Yamashita K., Kimura T., Teraoka K., et al. Changes of microvessels in the brain with Alzheimer's disease. Ann N Y Acad Sci 826 (1997) 428-432
17. de la Torre J.C. Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann N Y Acad Sci 826 (1997) 75-91
18. de la Torre J.C. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann N Y Acad Sci 924 (2000) 136-152
19. de la Torre J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33 (2002) 1152-1162
20. de la Torre J.C. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol Res 26 (2004) 517-524
21. Kumar-Singh S., Cras P., Wang R., Kros J.M., van Swieten J., Lubke U., et al. Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric. Am J Pathol 161 (2002) 507-520
22. Kumar-Singh S., Pirici D., McGowan E., Serneels S., Ceuterick C., Hardy J., et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 167 (2005) 527-543
23. Wu C.W., Liao P.C., Yu L., Wang S.T., Chen S.T., Wu C.M., et al. Hemoglobin promotes Abeta oligomer formation and localizes in neurons and amyloid deposits. Neurobiol Dis 17 (2004) 367-377
24. Cullen K., Kocsi Z., and Stone J. Pericapillary haem-rich deposits: evidence for microhaemorrhages in aging human cerebral cortex. J Cereb Blood Flow Metab 25 (2005) 1656-1667
25. Cullen K., Kosci Z., and Stone J. Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging (2006)
26. Hardy J. An 'anatomical cascade hypothesis' for Alzheimer's disease. Trends Neurosci 15 (1992) 200-201
27. Cullen K.M., Kocsi Z., and Stone J. Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging 27 (2006) 1786-1796
28. de la Torre J.C., Fortin T., Park G.A., Butler K.S., Kozlowski P., Pappas B.A., et al. Chronic cerebrovascular insufficiency induces dementia-like deficits in aged rats. Brain Res 582 (1992) 186-195
29. J. delaTorre, V. Hachinski, (Eds.), Cerebrovascular pathology in Alzheimer's disease; 1997.
30. Sharp F., Ran R., Lu A., Tang Y., Strauss K., Glass T., et al. Hypoxic preconditioning protects against ischemic brain injury. NeuroRx 1 (2004) 26-35
31. Bergeron M., Yu A., Solway K., Semenza G., and Sharp F. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci 11 (1999) 4159-4170
32. Aliev G., Smith M.A., Seyidov D., Neal M.L., Lamb B.T., Nunomura A., et al. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol 12 (2002) 21-35
33. 2+ channels in PC12 cells via increased amyloid beta peptide formation and reactive oxygen species generation. J Physiol 541 (2002) 1013-1023
34. Rottkamp C.A., Atwood C.S., Joseph J.A., Nunomura A., Perry G., and Smith M.A. The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease. Peptides 23 (2002) 1333-1341
35. Peers C., Pearson H.A., and Boyle J.P. Hypoxia and Alzheimer's disease. Essays Biochem 43 (2007) 153-164
36. Pluta R., Ulamek M., and Januszewski S. Micro-blood-brain barrier openings and cytotoxic fragments of amyloid precursor protein accumulation in white matter after ischemic brain injury in long-lived rats. Acta Neurochir Suppl 96 (2006) 267-271
37. Aliyev A., Chen S.G., Seyidova D., Smith M.A., Perry G., de la Torre J., et al. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. J Neurol Sci 229-230 (2005) 285-292
38. Wagner K., Sharp F.R., Ardizzone T.D., Lu A., and Clark J.F. Heme and iron metabolism: role in cerebral hemorrhage. J Cerebral Blood Flow Metabolism 23 (2003) 629-652
39. Yang S.P., Bae D.G., Kang H.J., Gwag B.J., Gho Y.S., and Chae C.B. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 25 (2004) 283-290
40. Tarkowski E., Issa R., Sjogren M., Wallin A., Blennow K., Tarkowski A., et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 23 (2002) 237-243
41. Smith M.A. Oxidative stress and iron imbalance in Alzheimer disease: how rust become the fuss!. J Alz Dis 9 (2006) 305-308
42. Perry G., Nunomura A., Hirai K., Zhu X., Perez M., Avila J., et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radic Biol Med 33 (2002) 1475-1479
43. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropath Exp Neurol 60 (2004) 759-767
44. Rogers J., Webster S., Lih-Fen L., Brachova L., Civin W., Emmerling M., et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 17 (1996) 681-686
45. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21 (2000) 383-421
46. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury Jr. P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418 (2002) 291
47. Lashuel H.A. Membrane permeabilization: a common mechanism in protein-misfolding diseases. Sci Aging Knowledge Environ 2005 (2005) pe28
48. De Jong G.I., Farkas E., Stienstra C.M., Plass J.R., Keijser J.N., de la Torre J.C., et al. Cerebral hypoperfusion yields capillary damage in the hippocampal CA1 area that correlates with spatial memory impairment. Neuroscience 91 (1999) 203-210
49. Jellinger K.A. The pathology of ischemic-vascular dementia: an update. J Neurol Sci 203-204 (2002) 153-157
50. Markesbery W.R., and Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol 9 (1999) 133-146
51. Nunomura A., Chiba S., Lippa C.F., Cras P., Kalaria R.N., Takeda A., et al. Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiol Dis 17 (2004) 108-113
52. Sheng J.G., Zhou X.Q., Mrak R.E., and Griffin W.S. Progressive neuronal injury associated with amyloid plaque formation in Alzheimer disease. J Neuropathol Exp Neurol 57 (1998) 714-717
53. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451 (2008) 720-724
54. McGeer P., McGeer E., Rogers J., and Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet 335 (1991) 1037
55. Jenkinson M.L., Bliss M.R., Brain A.T., and Scott D.L. Rheumatiod arthritis and senile dementia of the Alzheimer's type. Brit J Rheumat 28 (1989) 86-88
56. Sugaya K., Uz T., Kumar V., and Manev H. New anti-inflammatory treatment strategy in Alzheimer's disease. Jpn J Pharmacol 82 (2000) 85-94
57. Broe G.A., Grayson D.A., Creasey H.M., Waite L.M., Casey B.J., Bennett H.P., et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 57 (2000) 1586-1591
58. Breitner J.C., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 16 (1995) 523-530
59. McGeer P., Schulzer M., and McGeer E. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease. Neurology 47 (1996) 425-432
60. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23 (2004) 159-169
61. Miida T., Hirayama S., and Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb 11 (2004) 253-264
62. Liao J.K., and Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol 45 (2005) 89-118
63. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62 (2005) 753-757
64. Hill J.M., Steiner I., Matthews K.E., Trahan S.G., Foster T.P., and Ball M.J. Statins lower the risk of developing Alzheimer's disease by limiting lipid raft endocytosis and decreasing the neuronal spread of Herpes simplex virus type 1. Med Hypotheses 64 (2005) 53-58
65. Eckert G.P., Wood W.G., and Müller W.E. Statins: drugs for Alzheimer's disease?. J Neural Transm 112 (2005) 1057-1071
66. Menge T., Hartung H.P., and Stuve O. Statins--a cure-all for the brain?. Nature Rev Neurosci 6 (2005) 325-331
67. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiat 62 (2005) 217-224
68. Ledesma M.D., and Dotti C.G. The conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system. Biochem Soc Symp (2005) 129-138
69. Pedrini S., Carter T.L., Prendergast G., Petanceska S., Ehrlich M.E., and Gandy S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2 (2005) e18
70. Breteler M.M., Bots M.L., Ott A., and Hofman A. Risk factors for vascular disease and dementia. Haemostasis 28 (1998) 167-173
71. Breteler M.M. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21 (2000) 153-160
72. Decarli C. Vascular factors in dementia: an overview. J Neurol Sci 226 (2004) 19-23
73. Launer L.J. The epidemiologic study of dementia: a life-long quest? Neurobiol Aging 26 (2005) 335-340
74. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 105 (1998) 415-422
75. Finch C.E., and Cohen D.M. Aging, metabolism, and Alzheimer disease: review and hypotheses. Exp Neurol 143 (1997) 82-102
76. Messier C. Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol 38 (2003) 941-946
77. Jellinger K.A. Head injury and dementia. Curr Opin Neurol 17 (2004) 719-723
78. Starkstein S.E., and Jorge R. Dementia after traumatic brain injury. Int Psychogeriatr 17 Suppl 1 (2005) S93-S107
79. Mendez M.F. The neuropsychiatric aspects of boxing. Int J Psychiat Med 25 (1995) 249-262
80. Plassman B.L., Havlik R.J., Steffens D.C., Helms M.J., Newman T.N., Drosdick D., et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 55 (2000) 1158-1166
81. Jordan B.D. Chronic traumatic brain injury associated with boxing. Semin Neurol 20 (2000) 179-185
82. Roberts A. Brain damage in boxers (1969), Pitmen Medical Scientific Publishing, London
83. Erlanger D.M., Kutner K.C., Barth J.T., and Barnes R. Neuropsychology of sports-related head injury: dementia pugilistica to post concussion syndrome. Clin Neuropsychol 13 (1999) 193-209
84. Dale G.E., Leigh P.N., Luthert P., Anderton B.H., and Roberts G.W. Neurofibrillary tangles in dementia pugilistica are ubiquitinated. J Neurol Neurosurg Psychiatry 54 (1991) 116-118
85. Tokuda T., Ikeda S., Yanagisawa N., Ihara Y., and Glenner G.G. Re-examination of ex-boxers' brains using immunohistochemistry with antibodies to amyloid beta-protein and tau protein. Acta Neuropathol (Berl) 82 (1991) 280-285
86. McKenzie J.E., Roberts G.W., and Royston M.C. Comparative investigation of neurofibrillary damage in the temporal lobe in Alzheimer's disease, Down's syndrome and dementia pugilistica. Neurodegeneration 5 (1996) 259-264
87. Allsop D., Haga S., Bruton C., Ishii T., and Roberts G.W. Neurofibrillary tangles in some cases of dementia pugilistica share antigens with amyloid beta-protein of Alzheimer's disease. Am J Pathol 136 (1990) 255-260
88. Perry E.K. Nerve growth factor and the basal forebrain cholinergic system: a link in the etiopathology of neurodegenerative dementias?. Alzheimer Dis Assoc Disord 4 (1990) 1-13
89. Schmidt M.L., Zhukareva V., Newell K.L., Lee V.M., and Trojanowski J.Q. Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease. Acta Neuropathol (Berl) 101 (2001) 518-524
90. Mayeux R., Ottman R., Maestre G., Ngai C., Tang M.X., Ginsberg H., et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 45 (1995) 555-557
91. Smith J.D. Apolipoprotein E4: an allele associated with many diseases. Ann Med 32 (2000) 118-127
92. Mayeux R., and Schupf N. Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine. Am J Public Health 85 (1995) 1280-1284
93. Martland H. Punch drunk. J Am Med Assoc 91 (1928) 1103-1107
94. Maxwell W.L., Irvine A., Adams J.H., Graham D.I., and Gennarelli T.A. Response of cerebral microvasculature to brain injury. J Pathol 155 (1988) 327-335
95. Manley G.T., Rosenthal G., Lam M., Morabito D., Yan D., Derugin N., et al. Controlled cortical impact in swine: pathophysiology and biomechanics. J Neurotrauma 23 (2006) 128-139
96. Gentleman S.M., Nash M.J., Sweeting C.J., Graham D.I., and Roberts G.W. Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci Lett 160 (1993) 139-144
97. Roberts G.W., Gentleman S.M., Lynch A., Murray L., Landon M., and Graham D.I. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiat 57 (1994) 419-425
98. Ikonomovic M.D., Uryu K., Abrahamson E.E., Ciallella J.R., Trojanowski J.Q., Lee V.M., et al. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 190 (2004) 192-203
99. Katzman R. Apolipoprotein E and Alzheimer's disease. Curr Opin Neurobiol 4 (1994) 703-707
100. Strittmatter W., and Roses A. Apolipoprotein E and Alzheimer's disease. Ann Rev Neurosci 19 (1996) 53-77
101. Reiman E., Caselli R., Yun L., Chen K., Bandy D., Minoshima S., et al. Preclinical evidence of Alzheimer's disease in persons homoyzous for the 4 allele for apolipoprotein E. New Eng J Med 334 (1996) 752-758
102. Selkoe D.J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275 (1997) 630-631
103. Sing C.F., and Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37 (1985) 268-285
104. Finch C.E. Developmental origins of aging in brain and blood vessels: an overview. Neurobiol Aging 26 (2005) 281-291
105. Scuteri A., Bos A.J., Zonderman A.B., Brant L.J., Lakatta E.G., and Fleg J.L. Is the apoE4 allele an independent predictor of coronary events?. Am J Med 110 (2001) 28-32
106. Luthra K., Tripathi M., Grover R., Dwivedi M., Kumar A., and Dey A.B. Apolipoprotein E gene polymorphism in Indian patients with Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 17 (2004) 132-135
107. Panza F., D'Introno A., Colacicco A.M., Capurso C., Capurso S., Kehoe P.G., et al. Vascular genetic factors and human longevity. Mech Ageing Dev 125 (2004) 169-178
108. Wakutani Y., Kowa H., Kusumi M., Yamagata K., Wada-Isoe K., Adachi Y., et al. Genetic analysis of vascular factors in Alzheimer's disease. Ann N Y Acad Sci 977 (2002) 232-238
109. Hui D.Y., and Basford J.E. Distinct signaling mechanisms for apoE inhibition of cell migration and proliferation. Neurobiol Aging 26 (2005) 317-323
110. Goldgaber D. My story: the discovery and mapping to chromosome 21 of the Alzheimer amyloid gene. J Alz Dis 9 (2006) 349-360
111. Rehder H. Pathology of trisomy 21-with particular reference to persistent common atrioventricular canal of the heart. Hum Genet Suppl 2 (1981) 57-73
112. Wisniewski T., and Frangione B. Molecular biology of Alzheimer's amyloid-Dutch variant. Mol Neurobiol 6 (1992) 75-86
113. Frangione B., Revesz T., Vidal R., Holton J., Lashley T., Houlden H., et al. Familial cerebral amyloid angiopathy related to stroke and dementia. Amyloid 8 Suppl 1 (2001) 36-42
114. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. Alzheimer-type neuropathology in transgenic mice expressing V717F β-amyloid precursor protein. Nature 373 (1995) 523-527
115. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
116. Holcomb L., Gordon M., McGowan E., Yu X., Benkovic S., Jantzen P., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Medicine 4 (1998) 97
117. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94 (1997) 13287-13292
118. Games D., Buttini M., Kobayashi D., Schenk D., and Seubert P. Mice as models: transgenic approaches and Alzheimer's disease. J Alz Dis 9 (2006) 133-149
119. Falangola M.F., Lee S.P., Nixon R.A., Duff K., and Helpern J.A. Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res 30 (2005) 201-205
120. Winkler D., Bondolfi L., Herzig M.C., Jann L., Calhoun M.E., Wiederhold K.H., et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 21 (2001) 1619-1627
121. de la Torre J.C. Critical threshold cerebral hypoperfusion causes Alzheimer's disease?. Acta Neuropathol (Berl) 98 (1999) 1-8
122. Lansbury P.T., and Lashuel H.A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443 (2006) 774-779
123. Lashuel H.A., and Lansbury Jr. P.T. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?. Quart Rev Biophys 39 (2006) 167-201